Clinical Trial Update: ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating asciminib, alone or in combination with dasatinib, as second-line therapy for chronic myeloid leukemia in chronic phase; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Asciminib (asciminib)
• DASATINIB (Dasatinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Myeloid Leukemia (CML) in | Phase 2 | Status: NOT_YET_RECRUITING